Table 2

PsA clinical characteristics at baseline

UST (n=426)TNFi (n=442)
Psoriasis BSA, n (%) (95% CI)
 Clear/almost clear skin99 (28.8) (24.1 to 33.9)123 (34.1) (29.2 to 39.2)
 <3% but not clear/almost clear skin33 (9.6) (6.7 to 13.2)58 (16.1) (12.4 to 20.3)
 3%‒10%120 (34.9) (29.9 to 40.2)129 (35.7) (30.8 to 40.9)
 >10%92 (26.7) (22.1 to 31.8)51 (14.1) (10.7 to 18.2)
PsA characteristics, n (%) (95% CI)
 Axial involvement—pure or combined with peripheral147 (35.4) (30.8 to 40.2)161 (37.2) (32.6 to 41.9)
 Oligoarticular93 (22.4) (18.5 to 26.7)125 (28.9) (24.6 to 33.4)
 Polyarticular277 (66.7) (62.0 to 71.3)280 (64.7) (60.0 to 69.2)
Swollen joint count—66 joints (95% CI)6.0 (8.1) (5.2 to 6.8)5.8 (7.4) (5.1 to 6.5)
Tender joint count—68 joints (95% CI)12.5 (12.5) (11.2 to 13.7)11.3 (10.8) (10.3 to 12.4)
cDAPSA (95% CI)31.0 (20.3) (28.9 to 33.1)29.8 (18.6) (27.9 to 31.7)
Enthesitis at baseline, n (%) (95% CI)199 (48.9) (43.9 to 53.9)218 (51.9) (47.0 to 56.8)
Dactylitis at baseline, n (%) (95% CI)80 (18.8) (15.2 to 22.9)92 (20.8) (17.1 to 24.9)
Total PsAID-12 score (95% CI)5.7 (2.2) (5.5 to 5.9)5.5 (2.1) (5.3 to 5.7)
FiRST score ≥5, n (%) (95% CI)160 (39.3) (34.5 to 44.2)121 (29.0) (24.7 to 33.6)
ACPA positive, n (%) (95% CI)3.0 (3.2) (0.7 to 9.1)4.0 (2.9) (0.8 to 7.2)
RF positive, n (%) (95% CI)3.0 (2.1) (0.4 to 5.9)11 (5.8) (2.9 to 10.1)
CRP, mg/dL1.3 (3.0) (1.0 to 1.7)1.6 (2.9) (1.2 to 1.9)
  • Data are mean (SD) (95% CI of the mean) unless otherwise stated; % is that of available data. Numbers in bold indicate where significant differences exist at baseline.

  • ACPA, anti-citrullinated protein antibody; BSA, body surface area; cDAPSA, clinical Disease Activity Index for Psoriatic Arthritis; CRP, C-reactive protein; FiRST, Fibromyalgia Rapid Screening Tool; PsA, psoriatic arthritis; PsAID-12, 12-item Psoriatic Arthritis Impact of Disease questionnaire; RF, rheumatoid factor; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab.